Vaccinex, Inc. (NASDAQ:VCNX) Sees Large Decline in Short Interest

Vaccinex, Inc. (NASDAQ:VCNX) saw a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 62,100 shares, a decline of 44.7% from the November 15th total of 112,200 shares. Based on an average daily volume of 106,300 shares, the days-to-cover ratio is presently 0.6 days. Currently, 4.7% of the company’s stock are sold short.

Institutional Investors Weigh In On Vaccinex

A hedge fund recently raised its stake in Vaccinex stock. Point72 Asset Management L.P. raised its holdings in shares of Vaccinex, Inc. (NASDAQ:VCNX) by 42.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 166,000 shares of the company’s stock after purchasing an additional 49,454 shares during the period. Point72 Asset Management L.P. owned about 9.60% of Vaccinex worth $564,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 50.11% of the company’s stock.

Vaccinex Stock Up 1.5 %

Shares of VCNX opened at $4.05 on Thursday. Vaccinex has a 52-week low of $1.39 and a 52-week high of $13.02. The firm has a market cap of $10.53 million, a price-to-earnings ratio of -0.08 and a beta of 1.10. The business’s 50 day moving average is $3.21 and its two-hundred day moving average is $4.89.

Vaccinex Company Profile

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.